143 related articles for article (PubMed ID: 31730589)
1. Options for patients with metastatic colorectal cancer who progress after second-line therapy.
Marshall JL
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):2-4. PubMed ID: 31730589
[No Abstract] [Full Text] [Related]
2. Sequencing beyond the second-line setting in metastatic colorectal cancer: further observations.
Grothey A; Marshall JL; Bekaii-Saab T
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):16-18. PubMed ID: 31730592
[No Abstract] [Full Text] [Related]
3. Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):5-13. PubMed ID: 31730590
[No Abstract] [Full Text] [Related]
4. Management of patients with relapsed/refractory metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):14-16. PubMed ID: 31730591
[No Abstract] [Full Text] [Related]
5. First-line treatment options for patients with metastatic colorectal cancer.
Schilsky RL
Nat Clin Pract Oncol; 2004 Dec; 1(2):70-1. PubMed ID: 16264820
[No Abstract] [Full Text] [Related]
6. The handling of metastatic colorectal cancer.
Fornarini G; Guglielmi A; Sobrero A
Ann Oncol; 2005; 16 Suppl 2():ii141-3. PubMed ID: 15958445
[No Abstract] [Full Text] [Related]
7. Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
Calvo E
Clin Colorectal Cancer; 2002 Nov; 2(3):170-2. PubMed ID: 12482333
[No Abstract] [Full Text] [Related]
8. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
9. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
10. [Advance of salvage chemotherapy for colorectal cancer].
Aiba K; Natori K
Gan To Kagaku Ryoho; 2015 Apr; 42(4):394-7. PubMed ID: 25963685
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.
Hobday TJ; Goldberg RM
Clin Colorectal Cancer; 2002 Nov; 2(3):161-9. PubMed ID: 12482332
[TBL] [Abstract][Full Text] [Related]
12. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
Satoh T
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
[No Abstract] [Full Text] [Related]
13. Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma.
Kang EJ; Choi YJ; Kim JS; Kim ST; Park KH; Choi IK; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2010 Dec; 6(4):286-91. PubMed ID: 21114778
[TBL] [Abstract][Full Text] [Related]
14. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
15. Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer.
Prescrire Int; 2013 May; 22(138):120. PubMed ID: 23819169
[TBL] [Abstract][Full Text] [Related]
16. Current perspectives in the treatment of metastatic colorectal cancer.
Köhne CH; Folprecht G
Ann Oncol; 2004; 15 Suppl 4():iv43-53. PubMed ID: 15477334
[No Abstract] [Full Text] [Related]
17. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
18. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients.
Puzzoni M; Ziranu P; Demurtas L; Lai E; Mariani S; Liscia N; Soro P; Pretta A; Impera V; Camera S; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Scartozzi M
Future Oncol; 2020 Jan; 16(2):4337-4339. PubMed ID: 31793396
[No Abstract] [Full Text] [Related]
19. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy in metastatic colorectal cancer.
Marshall JL
Clin Adv Hematol Oncol; 2014 Jun; 12(6):388-90. PubMed ID: 25003569
[No Abstract] [Full Text] [Related]
[Next] [New Search]
